Logo image of MOR

MorphoSys AG (MOR) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:MOR - US6177602025 - ADR

18.96 USD
+0.45 (+2.43%)
Last: 8/2/2024, 8:20:34 PM
18.96 USD
0 (0%)
After Hours: 8/2/2024, 8:20:34 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to MOR. MOR was compared to 531 industry peers in the Biotechnology industry. Both the profitability and financial health of MOR have multiple concerns. MOR is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year MOR has reported negative net income.
MOR had a negative operating cash flow in the past year.
MOR had negative earnings in 4 of the past 5 years.
MOR had negative operating cash flow in 4 of the past 5 years.
MOR Yearly Net Income VS EBIT VS OCF VS FCFMOR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200M -400M

1.2 Ratios

MOR has a better Return On Assets (-25.13%) than 75.44% of its industry peers.
Industry RankSector Rank
ROA -25.13%
ROE N/A
ROIC N/A
ROA(3y)-11.93%
ROA(5y)-10.13%
ROE(3y)-230.96%
ROE(5y)-140.65%
ROIC(3y)N/A
ROIC(5y)N/A
MOR Yearly ROA, ROE, ROICMOR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100 -200 -300

1.3 Margins

MOR has a Gross Margin of 83.89%. This is amongst the best in the industry. MOR outperforms 88.68% of its industry peers.
MOR's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for MOR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 83.89%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.84%
GM growth 5Y-4.24%
MOR Yearly Profit, Operating, Gross MarginsMOR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100 -200

More info and screens

2

2. Health

2.1 Basic Checks

MOR does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MOR has been increased compared to 1 year ago.
The number of shares outstanding for MOR has been increased compared to 5 years ago.
The debt/assets ratio for MOR has been reduced compared to a year ago.
MOR Yearly Shares OutstandingMOR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M
MOR Yearly Total Debt VS Total AssetsMOR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B 2B 2.5B

2.2 Solvency

MOR has an Altman-Z score of -0.83. This is a bad value and indicates that MOR is not financially healthy and even has some risk of bankruptcy.
MOR's Altman-Z score of -0.83 is in line compared to the rest of the industry. MOR outperforms 58.54% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -0.83
ROIC/WACCN/A
WACC6.75%
MOR Yearly LT Debt VS Equity VS FCFMOR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M -400M 600M

2.3 Liquidity

A Current Ratio of 1.38 indicates that MOR should not have too much problems paying its short term obligations.
The Current ratio of MOR (1.38) is worse than 83.62% of its industry peers.
MOR has a Quick Ratio of 1.38. This is a normal value and indicates that MOR is financially healthy and should not expect problems in meeting its short term obligations.
MOR has a Quick ratio of 1.38. This is amonst the worse of the industry: MOR underperforms 81.71% of its industry peers.
Industry RankSector Rank
Current Ratio 1.38
Quick Ratio 1.38
MOR Yearly Current Assets VS Current LiabilitesMOR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M 1B

More info and screens

6

3. Growth

3.1 Past

The earnings per share for MOR have decreased strongly by -160.42% in the last year.
Looking at the last year, MOR shows a very negative growth in Revenue. The Revenue has decreased by -31.97% in the last year.
Measured over the past years, MOR shows a very strong growth in Revenue. The Revenue has been growing by 25.53% on average per year.
EPS 1Y (TTM)-160.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-518.18%
Revenue 1Y (TTM)-31.97%
Revenue growth 3Y-10.08%
Revenue growth 5Y25.53%
Sales Q2Q%-55.81%

3.2 Future

The Earnings Per Share is expected to grow by 23.09% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 33.46% on average over the next years. This is a very strong growth
EPS Next Y20.86%
EPS Next 2Y18.1%
EPS Next 3Y21.29%
EPS Next 5Y23.09%
Revenue Next Year-3.33%
Revenue Next 2Y12.61%
Revenue Next 3Y22.79%
Revenue Next 5Y33.46%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MOR Yearly Revenue VS EstimatesMOR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M 1B
MOR Yearly EPS VS EstimatesMOR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 -1 -2 -3

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MOR. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MOR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MOR Price Earnings VS Forward Price EarningsMOR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MOR Per share dataMOR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8 -10

4.3 Compensation for Growth

A more expensive valuation may be justified as MOR's earnings are expected to grow with 21.29% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.1%
EPS Next 3Y21.29%

More info and screens

0

5. Dividend

5.1 Amount

MOR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MorphoSys AG

NASDAQ:MOR (8/2/2024, 8:20:34 PM)

After market: 18.96 0 (0%)

18.96

+0.45 (+2.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-29 2024-04-29/amc
Earnings (Next)08-29 2024-08-29/amc
Inst Owners1.03%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap2.86B
Revenue(TTM)203.50M
Net Income(TTM)-460.27M
Analysts70
Price Target5.06 (-73.31%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-57555.5%
Min EPS beat(2)-115317%
Max EPS beat(2)206.19%
EPS beat(4)2
Avg EPS beat(4)-28776.9%
Min EPS beat(4)-115317%
Max EPS beat(4)206.19%
EPS beat(8)4
Avg EPS beat(8)-14366.3%
EPS beat(12)6
Avg EPS beat(12)-9590.79%
EPS beat(16)8
Avg EPS beat(16)-7188.44%
Revenue beat(2)0
Avg Revenue beat(2)-26.57%
Min Revenue beat(2)-49.34%
Max Revenue beat(2)-3.8%
Revenue beat(4)0
Avg Revenue beat(4)-15.03%
Min Revenue beat(4)-49.34%
Max Revenue beat(4)-2.92%
Revenue beat(8)4
Avg Revenue beat(8)2.63%
Revenue beat(12)7
Avg Revenue beat(12)3.04%
Revenue beat(16)11
Avg Revenue beat(16)8.21%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)3.95%
EPS NQ rev (3m)2.22%
EPS NY rev (1m)8.07%
EPS NY rev (3m)-24.79%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.71%
Revenue NY rev (1m)-5.17%
Revenue NY rev (3m)-6.8%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12.84
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.38
EYN/A
EPS(NY)-0.91
Fwd EYN/A
FCF(TTM)-2.18
FCFYN/A
OCF(TTM)-2.16
OCFYN/A
SpS1.48
BVpS-1.9
TBVpS-10.14
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -25.13%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 83.89%
FCFM N/A
ROA(3y)-11.93%
ROA(5y)-10.13%
ROE(3y)-230.96%
ROE(5y)-140.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.84%
GM growth 5Y-4.24%
F-Score2
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 28.32%
Cap/Sales 1.23%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.38
Quick Ratio 1.38
Altman-Z -0.83
F-Score2
WACC6.75%
ROIC/WACCN/A
Cap/Depr(3y)143.67%
Cap/Depr(5y)216.4%
Cap/Sales(3y)7.08%
Cap/Sales(5y)8.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-160.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-518.18%
EPS Next Y20.86%
EPS Next 2Y18.1%
EPS Next 3Y21.29%
EPS Next 5Y23.09%
Revenue 1Y (TTM)-31.97%
Revenue growth 3Y-10.08%
Revenue growth 5Y25.53%
Sales Q2Q%-55.81%
Revenue Next Year-3.33%
Revenue Next 2Y12.61%
Revenue Next 3Y22.79%
Revenue Next 5Y33.46%
EBIT growth 1Y-97.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year42.77%
EBIT Next 3Y26.15%
EBIT Next 5Y18.59%
FCF growth 1Y50.66%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y48.85%
OCF growth 3YN/A
OCF growth 5YN/A

MorphoSys AG / MOR FAQ

What is the fundamental rating for MOR stock?

ChartMill assigns a fundamental rating of 2 / 10 to MOR.


Can you provide the valuation status for MorphoSys AG?

ChartMill assigns a valuation rating of 1 / 10 to MorphoSys AG (MOR). This can be considered as Overvalued.


What is the profitability of MOR stock?

MorphoSys AG (MOR) has a profitability rating of 1 / 10.


What is the expected EPS growth for MorphoSys AG (MOR) stock?

The Earnings per Share (EPS) of MorphoSys AG (MOR) is expected to grow by 20.86% in the next year.